Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvant
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A recombinant protein vaccine for the prevention of COVID-19, consisting of the stabilized prefusion SARS-CoV-2 spike protein derived from the ancestral D614 strain, produced using the baculovirus expression system, and formulated with the AS03 adjuvant. The vaccine is designed to elicit neutralizing antibodies targeting the spike protein of SARS-CoV-2. AS03 is an oil-in-water emulsion adjuvant containing α-tocopherol, squalene, and polysorbate 80, and is included to enhance immunogenicity and durability of the immune response. The primary indication is for immunization against COVID-19, both as a primary series and as a booster. Developed by Sanofi and GSK, the vaccine has been studied in phase 3 clinical trials as monovalent (D614) and as a formulation for booster and primary immunization in adults, including after priming with other COVID-19 vaccines[2][3][4][5].
- Brand names
- VidPrevtyn
- Other names
- SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvantmonovalent (D614)-AS03 SARS-CoV-2 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 recombinant protein vaccine monovalent D614 + AS03 adjuvant.